Seattle Genetics Inc. (SGEN: Quote) highlighted multiple ADCETRIS data presentations at the 9th International Symposium on Hodgkin Lymphoma or ISHL being held October 12-15, 2013 in Cologne, Germany.
ADCETRIS, an antibody-drug conjugate directed to CD30, which is expressed in classical Hodgkin lymphoma or HL and systemic anaplastic large cell lymphoma or sALCL, was granted accelerated approval by the U.S. Food and Drug Administration or FDA in August 2011 for relapsed HL and sALCL and conditional marketing authorization by the European Commission in October 2012 for relapsed or refractory HL and sALCL.
Jonathan Drachman, M.D., Chief Medical Officer and Executive Vice President, Research and Development at Seattle Genetics said, "In addition, we are evaluating ADCETRIS broadly in more than 20 ongoing clinical trials, including four global phase 3 trials in earlier lines of therapy for HL and mature T-cell lymphoma, as well as relapsed cutaneous T-cell lymphoma. Our goal is to establish ADCETRIS as the foundation of therapy for CD30-positive malignancies and improve the therapeutic outcome for patients."
Three oral and nine poster presentations at ISHL illustrate the broad clinical development program for ADCETRIS in HL, including data from a phase 1 frontline advanced HL trial and a poster presentation describing the ongoing global phase 3 ECHELON-1 clinical trial in frontline HL. Currently, ADCETRIS is not approved to treat newly diagnosed HL.
| || |
| To receive FREE breaking news email alerts for Seattle Genetics Inc. and others in your portfolio|
by RTT Staff Writer
For comments and feedback: email@example.com